Key facts
- Notable investors include Antler, SOSV, IndieBio.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Post Translational Medicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Post Translational Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Post Translational Medicines
Developer of proteomics-based therapeutics designed to restore cellular waste processing and address neurodegeneration. The company offers targeted modulation of lysosomal enzyme structure and selective binding to aged protein isoforms, enabling pharmaceutical companies, cosmetics companies, and research institutions to improve disease understanding and develop interventions for aging-related conditions.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Website
- ptmedicines.com/
- Ownership
- Privately Held (backing)
Post Translational Medicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Post Translational Medicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Post Translational Medicines in its N-PORT filings yet. We sweep new filings monthly.